Overexpression of TRIM25 in Lung Cancer Regulates Tumor Cell Progression

Technology in Cancer Research and Treatment

Volumn 15, Issue 5, 2016, Pages 707-715

  Qin, Ying ^a   Cui, He ^a   Zhang, Hua ^a  

^a Shandong Medical College   (China)

Author keywords

lentivirus; lung cancer esophageal cancer; NSCLC; RNAi; shRNA

Indexed keywords

DOXORUBICIN; MEMBRANE PROTEIN; PROTEIN MDM2; PROTEIN P53; SMALL INTERFERING RNA; TRIPARTITE MOTIF CONTAINING PROTEIN 25; UNCLASSIFIED DRUG; PROTEIN BINDING; TRANSCRIPTION FACTOR; TRIM25 PROTEIN, HUMAN; TRIPARTITE MOTIF PROTEIN; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRDU ASSAY; CELL CYCLE PROGRESSION; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DRUG SENSITIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG CANCER; MALE; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR CELL; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL CYCLE; CELL MOTION; DISEASE COURSE; DISEASE MODEL; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; RNA INTERFERENCE; TUMOR CELL LINE; TUMOR VOLUME; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HETEROGRAFTS; HUMANS; LUNG NEOPLASMS; MICE; PROTEIN BINDING; RNA INTERFERENCE; TRANSCRIPTION FACTORS; TRIPARTITE MOTIF PROTEINS; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 84987811503     PISSN: 15330346     EISSN: 15330338     Source Type: Journal    
DOI: 10.1177/1533034615595903     Document Type: Article

References (21)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
2. Miyazaki J, Hirota S, Abe T. Metastasis of lung cancer to the gastrointestinal tract, presenting with a volcano-like ulcerated mass. Dig Endosc. 2015;27(3):397–398.
3. Littlefield P, Jura N. EGFR lung cancer mutants get specialized. Proc Natl Acad Sci USA. 2013;110(38):15169–15170.
4. Bartis D, M N, Mahida RY, Eickelberg O, Thickett DR. Epithelial–mesenchymal transition in lung development and dase: does it exist and is it important? Thorax. 2014;69(8):760–765.
5. Wang Y, Wen M, Kwon Y. CUL4A induces epithelial–mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014 1 15;74(2):520–531.
6. Jefferies C, Wynne C, Higgs R. Antiviral TRIMs: friend or foe in autoimmune and autoinflammatory dase? Nat Rev Immunol. 2011;11(9):617–625.
7. Choudhury NR, Nowak JS, Zuo J, Rappsilber J, Spoel SH, Michlewski G. Trim25 is an RNA-specific activator of Lin28a/TuT4-mediated uridylation. Cell Rep. 2014;9(4):1265–1272.
8. Urano T, Saito T, Tsukui T. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 2002;417(6891):871–875.
9. Gack MU, Shin YC, Joo CH. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity. Nature. 2007;446(7138):916–920.
10. Zhao KW, Sikriwal D, Dong X, Guo P, Sun X, Dong JT. Oestrogen causes degradation of KLF5 by inducing the E3 ubiquitin ligase EFP in ER-positive breast cancer cells. Biochem J. 2011;437(2):323–333.
11. Ueyama K, Ikeda K, Sato W. Knockdown of Efp by DNA-modified small interfering RNA inhibits breast cancer cell proliferation and in vivo tumor growth. Cancer Gene Ther. 2010;17(9):624–632.
12. Dai H, Zhang P, Zhao S, Zhang J, Wang B. Regulation of the vascular endothelial growth factor and growth by estrogen and antiestrogens through Efp in Ishikawa endometrial carcinoma cells. Oncol Rep. 2009;21(2):395–401.
13. Fu J, Lv X, Lin H. Ubiquitin ligase cullin 7 induces epithelial–mesenchymal transition in human choriocarcinoma cells. J Biol Chem. 2010;285(14):10870–10879.
14. Horie K, Urano T, Inoue S. Efp as a new molecular target for breast cancer therapy. Anticancer Drugs. 2003;14(1):1–2.
15. Wang Y, Zhang P, Liu Z. CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to Erlotinib via transcriptional regulation of EGFR. Mol Cancer. 2014;13:252.
16. Nalepa G, Harper JW. Efp: a ring of independence? Nat Med. 2002;8(7):661–662.
17. Zou W, Zhang DE. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J Biol Chem. 2006;281(7):3989–3994.
18. Davis ME, Gack MU. Ubiquitination in the antiviral immune response. Virology. 2015;479-480:52–65.
19. Sakuma M, Akahira J, Suzuki T. Expression of estrogen-responsive finger protein (Efp) is associated with advanced dase in human epithelial ovarian cancer. Gynecol Oncol. 2005;99(3):664–670.
20. Suzuki T, Urano T, Tsukui T. Estrogen-responsive finger protein as a new potential biomarker for breast cancer. Clin Cancer Res. 2005;11(17):6148–6154.
21. Zou W, Wang J, Zhang DE. Negative regulation of ISG15 E3 ligase EFP through its autoISGylation. Biochem Biophys Res Commun. 2007;354(1):321–327.